Denali Therapeutics submitted a Biologics License Application (BLA) for its therapy and the FDA granted Priority Review.
1 report, 0 independent
Updated Jul 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Denali Therapeutics submitted a Biologics License Application (BLA) for its therapy and the FDA granted Priority Review.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Denali Therapeutics (United States)
company in South San Francisco, United States
Nothing else this week.
- FDA
Related events
- FDA granted Priority Review for the BLA submission of the SkinTE product.
- Mesoblast is seeking FDA review of the BLA for its product rexlemestrocel-L.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- The FDA and European Medicines Agency are harmonizing regulatory review of drug applications.
Coverage
Newest first; wire copies grouped- Unknown outlet